MedTrace Logo

Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)

NCT03247569 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-05-06

No results posted yet for this study

Summary

In order to understand the risks and benefits of edoxaban use in a real-world clinical setting in the NVAF indication, Daiichi-Sankyo Thailand proposed this non-interventional study (NIS) to gain insight into the safety (bleeding, liver adverse events, all-cause mortality and other adverse events) of edoxaban use in non-preselected patients with NVAF.

Conditions

Interventions

DRUG

Edoxaban

Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).

Sponsors & Collaborators

  • Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company

    lead INDUSTRY

Principal Investigators

  • Late Phase Operations Lead, Global Medical Affairs · Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company

  • Study Project Manager · Daiichi Sankyo (Thailand) Ltd., a Daiichi Sankyo Company

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-18
Primary Completion
2022-02-28
Completion
2022-02-28

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247569 on ClinicalTrials.gov